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Detecting Carbapenemase Producers in the Clinic
C. Giske
Karolinska University, Stockholm, Sweden
Carbapenem resistance among Klebsiella pneumoniae, is
increasing in many parts of the world, and the treatment
options for such strains are very limited. The mechanisms
are mainly transferable carbapenemases of K. pneumoniae
carbapenemase (KPC) or metallo-betalactamase (MBL) type
(mainly VIM), but also OXA-48 carbapenemases, as well as
extendedspectrum beta-lactamases or AmpC in combination
with porin loss. Infection control is of crucial importance for
combating such resistance, and depends on adequate detec-
tion of carbapenemase-producing isolates. Several authors
have reported on problems of detecting such isolates, and
the reasons and possible solutions are discussed.
Carbapenem-producers have carbapenem MICs below the
current clinical breakpoints of EUCAST and CLSI. However,
EUCASTs epidemiological cut-offs (ECOFFs) values, the limit
of the wild-type populations, have been found useful to
identify such carbapenemase-producers. Disk diffusion cor-
relates to the current MIC ECOFFs are under development,
and seem to be working equally well with the tentative
zone ECOFFs. In particular meropenem and ertapenem pro-
duce a good separation between wild-type isolates and
carbapenem-producers. Automated antimicrobial suscepti-
bility testing (AST) systems will in most cases detect all
carbapenemaseproducers when using ECOFFs actively when
reading the quantitative AST results.
Phenotypic tests for conﬁrmation of carbapenemase-
production comprise the modiﬁed Hodge test (MHT), and
in-house combination disks containing carbapenems in com-
bination with boronic acid (for KPC detection) or zinc
chelators (for MBL-detection). The MHT has high sensitiv-
ity for detection of KPC, but lower for MBL. Also, there are
problems with speciﬁcity, mainly with AmpC hyperproduc-
ers. The combination diskmethod has recently been updated
with the addition of cloxacillin as a third inhibitor, in order to
separate AmpC hyperproduction plus porin loss (synergy with
cloxacillin and boronic acid) from KPC (synergy with boronic
acid only). Further, dipicolinic acid has better speciﬁcity for
MBL-detection than EDTA.
Although the above mentioned recommendations seem
to identify carbapenemase-producers among K. pneumo-
niae, it is still uncertain whether they will be adequate
for detection of carbapenemases in other species of Enter-
obacteriaceae. Further, there are still concerns regarding
detection with automated AST-systems. Detection depends
on the carbapenems included in the test.
doi:10.1016/j.ijid.2010.02.1882
c
m
L
h
w
e
b
gts e179
1.002
linical Impact and Current Epidemiology of Carbapene-
ase producers
. Thomson
Creighton Unviversity School of Medicine, Omaha, NE, USA
Carbapenemase-producing pathogens have become a
ajor and increasing infectious disease threat. Their most
erious impact is the lack effective therapies for the infec-
ions they cause. Given that laboratory detection is often
oor, our understanding of their epidemiology is incom-
lete. Some types of carbapenemase producers are already
biquitous. For other types, there are known hotspots of
ccurrence. KPC producers are mostly detected in the
astern USA and Israel, but have also been detected in
ome European and Asian countries. Metallo-- lactamase
MBL) producers mostly occur in Asia, Europe, Australia
nd South America. OXAcarbapenemase have been detected
orldwide. The most rapidly spreading pathogens are
robably Acinetobacter baumannii that produce OXA car-
apenemases and KPC-producing Klebsiella pneumoniae.
owever, these enzymes also occur in species that are
ess closely monitored, e.g. OXA-producing Enterobacteri-
ceae and KPC-producing A. baumannii and P. aeruginosa.
here appears to be less rapid spread of Enterobacteriaceae,
seudomonas aeruginosa and Acinetobacter that produce
ransmissible MBLs, but this observation may be a reﬂection
f suboptimal laboratory testing rather than reality. Prompt
nd accurate laboratory detection is critical. Outbreaks
nd therapeutic failures have resulted from testing prob-
ems. Another problem is that carbapenemase producers,
specially K. pneumoniae and A. baumannii, are efﬁcient
cavengers of additional resistance mechanisms and, as a
onsequence, are constantly changing. In this sense, they
re a ‘‘moving target’’ and contemporary understandings
ay have reduced relevance to the therapeutic, diagnostic,
nd infection control challenges of the future. The current
eeds are for effective therapies, effective infection control
ased on better detection, education of health care profes-
ionals, and for research to provide better understandings
f the biology of these pathogens.
oi:10.1016/j.ijid.2010.02.1883
1.003
ontrolling the Spread of Carbapenemase-Producing Bac-
eria
. Schwaber
National Center for Infection Control, Tel Aviv, Israel
Background: During 2006, Israeli hospitals faced a
lonal outbreak of carbapenem-resistant Klebsiella pneu-
oniae, producing the serine carbapenemase KPC-3.
ocally-implemented infection control measures in affected
ospitals failed to contain spread. A nationwide intervention
as launched to contain the outbreak and introduce a strat-
gy to control future dissemination of antibiotic-resistant
acteria in hospitals.
Methods: In March 2007, the Ministry of Health issued
uidelines mandating physical separation of hospitalized
